

**Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer
Addendum: Additional EAG analyses undertaken following the second appraisal committee meeting**

Additional analyses of Oncotype DX versus usual practice including chemotherapy benefit based on naïve indirect comparisons of Study B20, Study B14 and TransATAC – LN0, NPI>3.4 subgroup

Table 1 presents estimated hazard ratios for chemotherapy versus no chemotherapy based on naïve indirect comparisons of Study B20, Study B14 and TransATAC.

Table 1: Hazard ratios for chemotherapy benefit by Oncotype DX risk score based on naïve indirect comparisons of Study B20, Study B14 and TransATAC

B20 versus B14				
Oncotype DX risk group	No chemotherapy 10-yr DMFS	Chemotherapy 10-yr DMFS	Estimated HR	
Low	93.20%	95.60%	0.64	
Intermediate	85.70%	89.10%	0.75	
High	69.50%	88.10%	0.35	
B20 versus TransATAC				
Oncotype DX risk group	No chemotherapy 10-yr DMFS	Chemotherapy 10-yr DMFS	Estimated HR	
Low	94.90%	95.60%	0.86	
Intermediate	87.70%	89.10%	0.88	
High	77.20%	88.10%	0.49	

Table 2 presents additional economic comparisons of Oncotype DX versus usual practice including chemotherapy benefit based on naïve indirect comparisons of Study B20, B14 and TransATAC. In each analysis, the modelled hazard ratio was calibrated against the estimates presented in Table 1. All analyses are based on the deterministic version of the EAG model.

Table 2: Additional analyses of Oncotype DX versus usual practice including chemotherapy benefit based on naïve indirect comparisons of Study B20, B14 and TransATAC – LN0, NPI>3.4 subgroup

Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER (per QALY gained)
Chemotherapy benefit based on indirect comparison of B20 and B14					
Oncotype DX	12.82	£10,664	0.03	£682	£24,334
No test	12.79	£9,981	-	-	-
Chemotherapy benefit based on indirect comparison of B20 and TransATAC					
Oncotype DX	12.74	£10,989	0.06	£525	£8,150
No test	12.68	£10,465	-	-	-